Chollet; Andre

Patent Applications and Registrations

Patent applications and USPTO patent grants for Chollet; Andre.The latest application filed is for "pyrrolidine derivatives as oxytocin/vasopressin v1a receptors antagonists".

Company Profile

3.9.11

Chollet; Andre - Plan-les-Ouates CH

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Oral formulations of pyrrolidine derivatives Grant 11,419,851 - Chollet , et al. August 23, 2	2022-08-23
Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists Grant 11,312,683 - Chollet April 26, 2	2022-04-26
Pyrrolidine Derivatives As Oxytocin/vasopressin V1a Receptors Antagonists App 20210047266 - CHOLLET; Andre	2021-02-18
Oral Formulations Of Pyrrolidine Derivatives App 20200281892 - CHOLLET; Andre ; et al.	2020-09-10
Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrro- lidin-3-one O-methyloxime, and methods of using the same Grant 10,752,583 - Chollet A	2020-08-25
Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists Grant 10,604,482 - Chollet	2020-03-31
Oral formulations of pyrrolidine derivatives Grant 10,478,420 - Chollet , et al. Nov	2019-11-19
Oral Formulations Of Pyrrolidine Derivatives App 20180311211 - CHOLLET; Andre ; et al.	2018-11-01
Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists Grant 10,047,048 - Chollet August 14, 2	2018-08-14
Pyrrolidine Derivatives As Oxytocin/vasopressin V1a Receptors Antagonists App 20180215708 - CHOLLET; Andre	2018-08-02
Oral formulations of pyrrolidine derivatives Grant 9,962,367 - Chollet , et al. May 8, 2	2018-05-08
Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrro- Lidin-3-one O-methyloxime, And Methods Of Using The Same App 20170320822 - CHOLLET; Andre	2017-11-09
Pyrrolidine Derivatives As Oxytocin/vasopressin V1a Receptors Antagonists App 20170240508 - CHOLLET; Andre	2017-08-24
Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrro- lidin-3-one O-methyloxime, and methods of using the same Grant 9,718,772 - Chollet August 1, 2	2017-08-01
Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists Grant 9,670,155 - Chollet June 6, 2	2017-06-06
Oral Formulations Of Pyrrolidine Derivatives App 20170065556 - Chollet; Andre ; et al.	2017-03-09
PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1a RECEPTORS ANTAGONISTS App 20160221944 - CHOLLET; Andre	2016-08-04
Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrro- Lidin-3-one O-methyloxime, And Methods Of Using The Same App 20160002160 - CHOLLET; Andre	2016-01-07
Oral Formulations Of Pyrrolidine Derivatives App 20150164859 - CHOLLET; Andre ; et al.	2015-06-18
Pyrrolidine Derivatives As Oxytocin/vasopressin V1a Receptors Antagonists App 20150073032 - CHOLLET; Andre	2015-03-12

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.